Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Similar articles for PubMed (Select 23527792)

1.

Gene-based therapy for alpha-1 antitrypsin deficiency.

Mueller C, Flotte TR.

COPD. 2013 Mar;10 Suppl 1:44-9. doi: 10.3109/15412555.2013.764978. Review.

PMID:
23527792
2.

Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results.

Flotte TR, Trapnell BC, Humphries M, Carey B, Calcedo R, Rouhani F, Campbell-Thompson M, Yachnis AT, Sandhaus RA, McElvaney NG, Mueller C, Messina LM, Wilson JM, Brantly M, Knop DR, Ye GJ, Chulay JD.

Hum Gene Ther. 2011 Oct;22(10):1239-47. doi: 10.1089/hum.2011.053. Epub 2011 Aug 24.

3.

Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults.

Brantly ML, Spencer LT, Humphries M, Conlon TJ, Spencer CT, Poirier A, Garlington W, Baker D, Song S, Berns KI, Muzyczka N, Snyder RO, Byrne BJ, Flotte TR.

Hum Gene Ther. 2006 Dec;17(12):1177-86.

PMID:
17115945
4.

Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy.

Brantly ML, Chulay JD, Wang L, Mueller C, Humphries M, Spencer LT, Rouhani F, Conlon TJ, Calcedo R, Betts MR, Spencer C, Byrne BJ, Wilson JM, Flotte TR.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16363-8. doi: 10.1073/pnas.0904514106. Epub 2009 Aug 12. Erratum in: Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17606.

5.

In vivo post-transcriptional gene silencing of alpha-1 antitrypsin by adeno-associated virus vectors expressing siRNA.

Cruz PE, Mueller C, Cossette TL, Golant A, Tang Q, Beattie SG, Brantly M, Campbell-Thompson M, Blomenkamp KS, Teckman JH, Flotte TR.

Lab Invest. 2007 Sep;87(9):893-902. Epub 2007 Jun 25.

6.

Gene therapy progress and prospects: alpha-1 antitrypsin.

Stecenko AA, Brigham KL.

Gene Ther. 2003 Jan;10(2):95-9. Review.

PMID:
12571637
7.

Therapeutic level of functional human alpha 1 antitrypsin (hAAT) secreted from murine muscle transduced by adeno-associated virus (rAAV1) vector.

Lu Y, Choi YK, Campbell-Thompson M, Li C, Tang Q, Crawford JM, Flotte TR, Song S.

J Gene Med. 2006 Jun;8(6):730-5.

PMID:
16518879
8.

Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method.

Chulay JD, Ye GJ, Thomas DL, Knop DR, Benson JM, Hutt JA, Wang G, Humphries M, Flotte TR.

Hum Gene Ther. 2011 Feb;22(2):155-65. doi: 10.1089/hum.2010.118. Epub 2010 Dec 12.

9.

Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression.

Mueller C, Chulay JD, Trapnell BC, Humphries M, Carey B, Sandhaus RA, McElvaney NG, Messina L, Tang Q, Rouhani FN, Campbell-Thompson M, Fu AD, Yachnis A, Knop DR, Ye GJ, Brantly M, Calcedo R, Somanathan S, Richman LP, Vonderheide RH, Hulme MA, Brusko TM, Wilson JM, Flotte TR.

J Clin Invest. 2013 Dec;123(12):5310-8. doi: 10.1172/JCI70314. Epub 2013 Nov 15.

10.

A review of augmentation therapy for alpha-1 antitrypsin deficiency.

Mohanka M, Khemasuwan D, Stoller JK.

Expert Opin Biol Ther. 2012 Jun;12(6):685-700. doi: 10.1517/14712598.2012.676638. Epub 2012 Apr 14. Review.

PMID:
22500781
11.

Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vector.

Conlon TJ, Cossette T, Erger K, Choi YK, Clarke T, Scott-Jorgensen M, Song S, Campbell-Thompson M, Crawford J, Flotte TR.

Mol Ther. 2005 Nov;12(5):867-75. Epub 2005 Aug 8.

PMID:
16085464
12.

Intrapleural administration of an AAVrh.10 vector coding for human α1-antitrypsin for the treatment of α1-antitrypsin deficiency.

Chiuchiolo MJ, Kaminsky SM, Sondhi D, Hackett NR, Rosenberg JB, Frenk EZ, Hwang Y, Van de Graaf BG, Hutt JA, Wang G, Benson J, Crystal RG.

Hum Gene Ther Clin Dev. 2013 Dec;24(4):161-73. doi: 10.1089/humc.2013.168.

PMID:
24191907
13.

Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults.

Flotte TR, Brantly ML, Spencer LT, Byrne BJ, Spencer CT, Baker DJ, Humphries M.

Hum Gene Ther. 2004 Jan;15(1):93-128.

PMID:
14965381
14.

The promise of gene therapy for the treatment of alpha-1 antitrypsin deficiency.

Cruz PE, Mueller C, Flotte TR.

Pharmacogenomics. 2007 Sep;8(9):1191-8. Review.

PMID:
17924834
15.

Gene therapy for alpha-1 antitrypsin deficiency.

Flotte TR, Mueller C.

Hum Mol Genet. 2011 Apr 15;20(R1):R87-92. doi: 10.1093/hmg/ddr156. Epub 2011 Apr 16. Review.

16.

Expression of human alpha1-antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs.

Halbert CL, Madtes DK, Vaughan AE, Wang Z, Storb R, Tapscott SJ, Miller AD.

Mol Ther. 2010 Jun;18(6):1165-72. doi: 10.1038/mt.2010.51. Epub 2010 Apr 6.

17.

Adipose tissue-derived mesenchymal stem cell-based liver gene delivery.

Li H, Zhang B, Lu Y, Jorgensen M, Petersen B, Song S.

J Hepatol. 2011 May;54(5):930-8. doi: 10.1016/j.jhep.2010.07.051. Epub 2010 Nov 3.

18.

Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies.

Turner AM.

BioDrugs. 2013 Dec;27(6):547-58. doi: 10.1007/s40259-013-0042-5. Review.

PMID:
23771682
19.

Phase I/II study of intrapleural administration of a serotype rh.10 replication-deficient adeno-associated virus gene transfer vector expressing the human α1-antitrypsin cDNA to individuals with α1-antitrypsin deficiency.

Chiuchiolo MJ, Kaminsky SM, Sondhi D, Mancenido D, Hollmann C, Crystal RG.

Hum Gene Ther Clin Dev. 2014 Sep;25(3):112-33. doi: 10.1089/humc.2014.2513. No abstract available.

PMID:
25238276
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk